Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Rituximab in PTLD
NCT00869323Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2009
- Primary completion
- Mar 2013
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Post-Transplant Lymphoproliferative Disorder (PTLD), sponsored by Masonic Cancer Center. Started Mar 2009; status: terminated.
02
Drugs
bortezomib
03
Conditions
Post-Transplant Lymphoproliferative Disorder (PTLD)
Beyond the preview
Go deeper on NCT00869323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00869323.